Skip to main content

ORGANOGENESIS SHAREHOLDER NOTICE


Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Organogenesis To Contact Him Directly To Discuss Their Options

 

NEW YORK, NY - (NewMediaWire) - December 4, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Organogenesis (“Organogenesis Holdings Inc.” or the “Company”) (NASDAQ: ORGO).

 

If you suffered losses exceeding $50,000 investing in Organogenesis stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/ORGO.

 

A person in a suit

Description automatically generated with medium confidence

 

There is no cost or obligation to you. 

 

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.


On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis Holdings, Inc., indicating that the wound care medical company has been improperly billing the federal government for $250 million annually. The Company also set the price for its new wound covering, Affinity, “exorbitantly high”, which Medicare reimbursed, while making the product lucrative for doctors to use through large rebates.


On this news the stock has dropped $1.70 or 14.11% to close at $10.35 on unusually high volume.


Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.